LLTech systems are intended to allow real-time cancer diagnosis in radiology suite, surgical suites and pathology labs. They provide real-time information to assess surgical margins and the validity of biopsies
Skin Mohs surgery: basal cell carcinoma
Mohs surgery aims to conserve precious skin by removing the minimum tissue around a basal cell tumor. Current practice involves frozen section observation, slice by slice of the tissue removed. The tissue is removed in several stages, each one lasting up to 1.5 hours. The LLTech technology offers a faster alternative. The potential benefits are:
- Higher productivity and more patients for the clinic.
- Shorter surgery for the patients: the procedure is finalized with one numbing instead of spending the better part of a day with an open wound on the face, up to 1.5 hours between each stage and being numbed multiple times.
This market represents 1.2 million procedures per year in the US and will be the first target market in the US for LLTech.
Surgical margins assessment starting with breast and ENT
The current unpopular intra-operative frozen section technique creates bottlenecks in the surgery workflow. Moreover, for complex surgeries where clear margins are difficult to confirm and for breast tissue, where frozen sections are not effective, reports from the pathology lab can take five days to two weeks, requiring additional surgery – up to 30 percent of the time. In that context, the potential benefits of using the LLTech systems are:
- Utilize Operating Room more efficiently
- Shorten duration of surgery
- Avoid repeat surgeries
- Serve more patients
- Improve patient experience
The first target applications are ENT (Ear, Nose, Throat) and breast cancer surgery.
Internal organ biopsies
Biopsies of internal organs (lung, liver, kidney, prostate, gastrointestinal system) are complex, expensive and have a significant failure rate (up to 20%). The consequense is recalling the patient and repeating the procedure.
Today, with the development of personalized medicine, biopsies must contain enough tumor so that all the appropriate tests and diagnosis (genetic profile) can be done. The requirement for more tissue, in conjunction with more non-invasive surgery, which aims to excise less tissue, is a more stringent requirement than before, when only a few cancerous cells where needed.
Radiologists and urologists see the LLTech system as the tool to ensure that the biopsy is adequate before the patient leaves.
The following results are very encouraging based on preliminary, peer reviewed, published studies:
- 100% detection of kidney tumors (30 samples).
- 100% sensitivity, 96% specificity for prostate tumors with Gleason score 6 and above (220 biopsies).
The LLTech technology could be used for:
- Sample qualification and triage.
- Quality control of samples preserved in tissue banks for graft and research.
- Storing a digital image catalog.